Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study by Burisch, J et al.
198
Journal of Crohn's and Colitis, 2018, 198–208
doi:10.1093/ecco-jcc/jjy154
Advance Access publication October 5, 2018
Original Article
Copyright © 2018 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved.  
For permissions, please email: journals.permissions@oup.com
Original Article
Natural Disease Course of Ulcerative Colitis 
During the First Five Years of Follow-up in a 
European Population-based Inception Cohort—
An Epi-IBD Study
Johan Burischa, , Konstantinos H. Katsanosb, Dimitrios K. Christodouloub, 
Luisa Barrosc, Fernando Magroc,d, Natalia Pedersene, Jens Kjeldsenf, , 
Zsuzsanna Veghg, Peter L. Lakatosg,h, Carl Erikssoni, , Jonas Halfvarsoni,  
Mathurin Fumeryj, Corinne Gower-Rousseauk,l, Marko Brinarm,n,  
Silvija Čuković-Čavkam,n, Inna Nikulinao, Elena Belousovao,  
Sally Myersp, Shaji Sebastianp, Gediminas Kiudelisq, Limas Kupcinskasq,r, 
Doron Schwartzs, Selwyn Odess, Ioannis P. Kaimakliotist, Daniela Valpianiu, 
Renata D’Incàv, Riina Saluperew, Stefania Chetcuti Zammitx,  
Pierre Ellulx, Dana Duricovay, Martin Bortliky,z, Adrian Goldisaa,  
Hendrika Adriana Linda Kievitbb, Alina Tocacc, Svetlana Turcancc, 
Jóngerð Midjorddd, Kári Rubek Nielsendd, Karina Winther Andersenee, 
Vibeke Andersenee,ff,gg, Ravi Misrahh, Naila Arebihh, Pia Oksanenii,jj, 
Pekka Collinii,jj, Luisa de Castrokk, Vicent Hernandezkk, , Ebbe Langholzll, 
Pia Munkholma; for the Epi-IBD Group
aDepartment of Gastroenterology, Nordsjællands Hospital, University of Copenhagen, Frederikssund, Denmark 
bDepartment of Gastroenterology, University Hospital of Ioannina, Ioannina, Greece cDepartment of Gastroenterology, 
Centro Hospitalar de São João EPE, Porto, Portugal dDepartment of Biomedicine, Institute of Pharmacology, Faculty 
of Medicine of Porto University, Porto, Portugal eGastroenterology Department, Slagelse Hospital, Slagelse, Denmark 
fGastroenterology Department, Odense University Hospital, Odense, Denmark gFirst Department of Medicine, 
Semmelweis University, Budapest, Hungary hDivision of Gastroenterology, McGill University Health Center, Montreal, 
QC, Canada iDepartment of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden 
jGastroenterology Unit, Epimad Registry, CHU Amiens Sud, Amiens University Hospital, Amiens, France kPublic Health, 
Epidemiology and Economic Health, Registre Epimad, Lille University and Hospital, Lille, France lLille Inflammation 
Research International Center LIRIC, Lille University, Lille, France mDivision of Gastroenterology and Hepatology, 
University Hospital Center Zagreb, Zagreb, Croatia nSchool of Medicine, University of Zagreb, Zagreb, Croatia 
oDepartment of Gastroenterology, Moscow Regional Research Clinical Institute, Moscow, Russian Federation pIBD 
Unit, Hull and East Yorkshire NHS Trust, Hull, UK qInstitute for Digestive Research, Medical Academy, Lithuanian 
University of Health Sciences, Kaunas, Lithuania rDepartment of Gastroenterology, Medical Academy, Lithuanian 
University of Health Sciences, Kaunas, Lithuania sDepartment of Gastroenterology and Hepatology, Soroka Medical 
Center and Ben Gurion University of the Negev, Beer Sheva, Israel tAmerican Gastroenterology Center, Nicosia, 
Cyprus uU.O. Gastroenterologia ed Endoscopia digestiva, Hospital Morgagni Pierantoni, Forlì, Italy vDepartment 
of Surgical, Oncological and Gastroenterological Sciences, Azienda, University of Padua, Padova, Italy wDivision 
of Gastroenterology, Tartu University Hospital, University of Tartu, Tartu, Estonia xDivision of Gastroenterology, 










niversity user on 07 July 2019
of Pharmacology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic aaClinic of 
Gastroenterology, University of Medicine ‘Victor Babes’, Timisoara, Romania bbDepartment of Medicine, Herning 
Central Hospital, Herning, Denmark ccDepartment of Gastroenterology, State University of Medicine and Pharmacy 
of the Republic of Moldova, Chisinau, Republic of Moldova ddMedical Department, National Hospital of the Faroe 
Islands, Torshavn, Faroe Islands eeMedical Department, Regional Hospital of Viborg, Viborg, Denmark ffFocused 
Research Unit for Molecular Diagnostic and Clinical Research [MOK], IRS-Center Sonderjylland, Hospital of 
Southern Jutland, Aabenraa, Denmark ggInstitute of Molecular Medicine, University of Southern Denmark, Odense, 
Denmark hhIBD Department, St Mark’s Hospital, London, UK iiDepartment of Gastroenterology and Alimentary Tract 
Surgery, Tampere University Hospital, Tampere, Finland jjUniversity of Tampere, Tampere, Finland kkDepartment of 
Gastroenterology. Hospital Alvaro Cunqueiro, Instituto Investigación Sanitaria Galicia Sur, EOXI de Vigo, Vigo, Spain 
llDepartment of Gastroenterology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
Corresponding author: Johan Burisch, MD, PhD, Department of Gastroenterology, 
North Zealand University Hospital, Frederikssundsvej 30, 3600 Frederikssund, Denmark.  
Email: johan.burisch@regionh.dk
Abstract
Background and Aims: Few population-based cohort studies have assessed the disease course of 
ulcerative colitis [UC] in the era of biological therapy and widespread use of immunomodulators. 
The aim of this study was to assess the 5-year outcome and disease course of patients with UC in 
the Epi-IBD cohort.
Methods: In a prospective, population-based inception cohort of unselected patients with UC, 
patients were followed up from the time of their diagnosis, which included the collection of their 
clinical data, demographics, disease activity, medical therapy, and rates of surgery, cancers, and 
deaths. Associations between outcomes and multiple covariates were analysed by Cox regression 
analysis.
Results: A total of 717 patients were included in the study. During follow-up, 43 [6%] patients 
underwent a colectomy and 163 [23%] patients were hospitalised. Of patients with limited colitis 
[distal to the left flexure], 90 [21%] progressed to extensive colitis. In addition, 92 [27%] patients 
with extensive colitis experienced a regression in disease extent, which was associated with a 
reduced risk of hospitalisation (hazard ratio [HR]: 0.5 95% CI: 0.3–0.8]. Overall, patients were treated 
similarly in both geographical regions; 80 [11%] patients needed biological therapy and 210 [29%] 
patients received immunomodulators. Treatment with immunomodulators was found to reduce 
the risk of hospitalisation [HR: 0.5 95% CI: 0.3–0.8].
Conclusions: Although patients in this population-based cohort were treated more aggressively 
with immunomodulators and biological therapy than in cohorts from the previous two decades, 
their disease outcomes, including colectomy rates, were no different. However, treatment with 
immunomodulators was found to reduce the risk of hospitalisation.
Key Words:  Ulcerative colitis; surgery; hospitalisation; prognosis; treatment; biologics
1. Introduction
Ulcerative colitis [UC] belongs to the group of inflammatory bowel 
diseases [IBD] and is a chronic, progressive disorder of unknown 
aetiology. Both its clinical presentation and its course vary between 
patients and can range from mostly quiescent to chronic, refractory 
disease in need of surgery, sometimes being complicated by cancer 
or contributing to cause of death.1 Recent treatment strategies for 
UC have been using immunomodulators and biological agents both 
earlier in the disease course and more frequently. The introduction of 
mucosal healing as an important treatment goal is likewise a recent 
development.2
The beneficial impact of biological therapy on the disease 
course of UC is partly supported by data from randomised con-
trolled trials3 and epidemiological studies,4,5 whereas the impact of 
immunomodulators remains uncertain. To date, there have been few 
population-based cohort studies from this era of widespread use of 
immunomodulators and biological therapy, and hence little is known 
about the present real-life disease outcomes of UC patients. To assess 
the impact of treatment strategies on disease outcome, prospective, 
population-based cohorts of unselected patients representing the 
broad spectrum of the disease are necessary in order to build the 
most accurate picture of effectiveness and practice regarding medica-
tion and surgery in the community setting.
The Epi-IBD [formerly EpiCom] study uses a prospective, 
population-based inception cohort of unselected IBD patients for 
investigating the occurrence, disease course, and prognosis of these 
diseases in Europe.6,7 The aim of the present study was to: [1] evalu-
ate the disease course of UC and the impact of treatment choices on 
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it during the first 5 years following diagnosis;, and [2] assess a pos-
sible west-east gradient in treatment strategies and disease outcomes 
within this cohort.
2. Methods
2.1. Study population and design
The Epi-IBD cohort is a prospective, population-based inception 
cohort of IBD patients diagnosed in 2010 in 22 European countries 
and Israel.8 Participating centres were required to have a well-defined 
primary catchment area with up-to-date population data, including 
age and sex distribution. They were also required to have an estab-
lished network of gastroenterologists, colorectal surgeons, and gen-
eral practitioners [GPs] within the uptake area to be contacted twice 
during the inclusion period, to ensure complete coverage and recruit-
ment of patients. Case ascertainment methods, diagnostic criteria, 
inclusion period, and patient data were all standardised.
Two centres [France, Malta] joined the study group after the 
start of the inclusion period, both of them having included inci-
dent patients in prospective, inception cohorts in 2010 in parallel. 
Five centres from the original cohort were unable to perform fol-
low-up for technical or logistical reasons. Consequently, 29 centres 
from eight Eastern, and 13 Western, European countries, including 
Israel, participated in the study [see Supplementary File, available as 
Supplementary data at ECCO-JCC online]. The study population 
consisted of 1289 IBD patients, 488 with Crohn’s disease [CD], 717 
with UC, and 84 with IBD unclassified [IBDU], all recruited within 
well-described geographical areas covering a total background 
population of 9.7 million people [2.6 million in Eastern, and 7.1 
million in Western, Europe].
2.2. Classifications and definitions
All incident patients diagnosed with IBD according to the Copenhagen 
Diagnostic Criteria9–11 between 1 January and 31 December 2010, 
aged 15 years or older and living in the predefined catchment areas 
at the time of diagnosis, were prospectively included. The date of 
inclusion was the date of their diagnosis. A small number of patients 
had their diagnosis changed during follow-up, and those patients 
were reclassified as having the newly diagnosed disease from the 
time of the original diagnosis.
Disease extent for UC was defined according to the Montreal 
Classification.12 Disease extension was defined as a proximal pro-
gression from the initial extent at diagnosis, as determined by endos-
copy. In cases where no investigative procedures were performed 
before surgery owing to acute symptoms, macroscopic description 
of the surgical specimen was used to describe the disease extent. 
Regression in extent was assessed by comparing the most recent 
endoscopic examination with the worst disease extent found pre-
viously. Hospitalisations were defined as either admission for 
UC-related surgery [surgical hospitalisations] or other UC-related 
complaints [medical hospitalisations]. Elective admissions, e.g. for 
endoscopy procedures or drug administration, were excluded from 
consideration.
Treatment was grouped into five levels of ascending therapeutic 
potency: 5-aminosalicylates [5-ASA] [oral and/or topical 5-ASA 
treatment ± topical steroids], glucocorticosteroids [GCS] [oral ster-
oids  ±  5-ASA or topical steroids], immunomodulators [azathio-
prine, 6-mercaptopurine, cyclosporine, or methotrexate ± steroids], 
biologics [infliximab or adalimumab, in combination with any of 
the above], and surgery [colectomy]. Immunomodulators were 
combined in one category because 95% of patients treated with 
immunomodulators received thiopurines. An early need for immu-
nomodulators or biological therapy was defined as the initiation of 
these drugs within 6 months of diagnosis. An early need for GCS was 
defined as patients starting on 40 mg or more of it within 30 days 
of their diagnosis.
The disease activity of UC was measured using the Simple Clinical 
Colitis Activity Index [SCCAI].13 A SCCAI score of ≤2 was defined as 
remission, 3–5 as mild, 6–11 as moderate, and ≥12 as severe disease 
activity.14 Causes of death and cancers were categorised according to 
the Tenthh revision of the International Classification of Diseases.15 
Endoscopic activity was determined using the Mayo endoscopic sub-
score16 and mucosal healing was defined as a subscore ≤1.
2.3. Data collection and validity
Incident patients were followed prospectively from their diagno-
sis for 5 years, or until the date of their emigration or death. Data 
regarding demographics, disease activity, medical therapy including 
dose, date of initiation and date of cessation, surgery, hospitalisation, 
disease classification, cancers and deaths were collected and entered 
prospectively in the web-based Epi-IBD database.17 A  follow-up 
period of 5 years, with a 3-month margin on either side, was chosen 
for assessing the outcome of the cohort. Measures to ensure data 
validity have been thoroughly described elsewhere6; in short, there 
were built-in control and validation tests, locked diagnostic criteria 
in the database, manual data standardisation, and random audits of 
case ascertainment and data quality.
2.4. Statistical analysis
Statistical analyses were performed using SAS software version 
9.4 [SAS Institute Inc., Cary, NC, USA]. Continuous variables are 
expressed as the median [interquartile range; IQR] unless otherwise 
stated. Groups were compared using a chi-square test or Fisher’s 
exact test, where appropriate. Differences regarding time to events 
were compared using the Wilcoxon two-sample test. A p-value of 
<0.05 was considered statistically significant.
Possible associations between primary endpoints [progression 
in disease extent, regression in disease extent, surgery, hospitalisa-
tion, or biological treatment] and multiple covariates were analysed 
by stepwise Cox regression analysis using the proportional hazards 
assumption, and associations were visualised by Kaplan–Meier plots 
in order to test these assumptions. As the aim was to describe the 
disease course following diagnosis, only events occurring after the 
date of diagnosis were included in the Cox regression analysis.
The following covariates were included in the statistical mod-
els: age at diagnosis [continuous variable], sex, geographical region 
[Western vs Eastern Europe], disease extent at diagnosis, smoking 
status [never, currently, former], diagnostic delay [continuous vari-
able], need for early corticosteroids, treatment with immunomodula-
tors, treatment with biologics, and regression in extent. The reported 
hazard ratios [HR] are all adjusted. The use of immunomodulators 
and biologics were included in the regression model as time-depend-
ent variables and with an initial lag time of 3  months for immu-
nomodulators and 2 months for biologics, so that only treatments 
before an event and lasting longer than the lag time would count as 
active treatment. We also included age and diagnostic delay as cat-
egorical variables, as well as smoking as a binary variable [current vs 
former/never smoker], with no impact on the results.
We demonstrated the prevalence of treatment types using two 
prevalence plots. In the first variant, each patient was classified, 
on any given day since their diagnosis, as being in one of the treat-
ment steps according to the treatment[s] received on that specific 
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day. In the case of combination therapy, the patient was counted 
for all treatment steps given. In the second variant [shown in the 
Supplementary File, available as Supplementary data at ECCO-JCC 
online], in the case of the patient receiving combination treatment, 
the level assigned was that of the most potent treatment. In both 
plots, patients undergoing surgery were considered as remaining in 
this treatment step for 1 year.
2.5. Ethical considerations
The study was approved by the local ethical committees and accord-
ing to local regulations.
3. Results
Initially, 701 patients aged 15 years or older were diagnosed with 
UC. During follow-up, 20 patients initially diagnosed with IBDU, 
and six diagnosed with CD, had their diagnosis changed to UC after 
a median of 6 months [IQR 3–12]. Furthermore, 10 patients initially 
diagnosed with UC had their diagnosis changed to CD and were 
excluded. As such, the cohort consisted of 717 UC patients, of whom 
591 [82%] were diagnosed in Western, and 126 [18%] in Eastern, 
European centres. These patients were followed for a median of 
63 months [IQR: 44–63]. Patients’ sociodemographic characteristics 
[Table 1] did not differ significantly between the two geographical 
regions, except in that more Eastern European patients had extra-
intestinal manifestations at diagnosis.
Data regarding disease activity during follow-up were available 
for analysis from 626 [87%] patients. The proportion of patients in 
clinical remission rose from 27% during the first year of disease to 
71% in the fifth year of follow-up [Figure 1].
3.1. Disease extent
Information about disease extent at diagnosis was not available in 
the case of nine [1%] patients, who were excluded from this part of 
the analysis. At the time of diagnosis, 435 [61%] patients had limited 
UC [E1, proctitis or E2, left-sided colitis], and during follow-up 90 
[21%] patients experienced a progression in extent, among whom 
67 [15%] patients progressed to E3 [extensive colitis] [Figure 2]. The 
median time to progression was 25  months [IQR: 12–28] for E1 
to E2, 17 months [IQR: 8–38] for progression from E1 to E3, and 
12 months [IQR: 7–22] for progression from E2 to E3. No statistic-
ally significant geographical differences were found in terms of the 
proportion of patients experiencing these progressions in disease nor 
length of time in which these progressions occurred. Predictors asso-
ciated with progression in extent are shown in Table 2.
Of patients diagnosed with extensive colitis, 69 [25%] regressed 
to either proctitis [n = 23, 33%] or left-sided colitis [n = 46, 67%] 
after a median of 41 months [IQR: 17–50] after diagnosis. Of those 
patients [n = 67] who progressed to extensive colitis during follow-
up, 23 [34%] later regressed to proctitis [n = 3, 13%] or left-sided 
colitis [n = 20, 87%] after a median of 27 months [IQR: 9–46] since 
they first progressed [Figure 2]. Overall, of patients with extensive 
colitis either at diagnosis or during follow-up, 92 [27%] regressed to 
a more limited disease extent.
We found no predictor for regression in extent among patients 
diagnosed with extensive colitis [Table  2]. For this subgroup we 
also analysed predictors of surgery and hospitalisation, including 
whether they regressed in disease extent or not. The results of this 
analysis are shown in Table 3; regression in extent was associated 
with a lower risk for all outcomes.
3.2. Medical treatment
The cumulative 5-year exposures to medical treatments are shown in 
Figure 3, and the median duration of treatment is shown in Table 1. 
Overall, the use of treatments was similar between Eastern and 
Western Europe. However, significantly more patients in Western 
Europe [7%] than in Eastern Europe [0%] received no treatment 
during follow-up [p < 0.01]. The distribution of patients between the 
defined treatment steps at any given time during follow-up is shown 
in Figure 4, and the pattern of changes between treatment steps is 
shown in Supplementary Figure 1, available as Supplementary data 
at ECCO-JCC online.
Table 1. Characteristics of incident ulcerative colitis patients from the Epi-IBD cohort.
All patients Western Europe [n = 591, 82%] Eastern Europe [n = 126, 18%]
Male, n [%] 397 [55%] 329 [56%] 68 [54%]
Age at diagnosis, years, [IQR] 37 [27–55] 38 [27–56] 35 [26–51]
Median time to diagnosis, months, [IQR] 3 [1–6] 3 [1–6] 2 [1–6]
Extra-intestinal manifestations at 
 diagnosis, n [%]
66 [9%] 48 [8%] 18 [14%]
Smoking status at diagnosis, n [%]
 Never smoker 368 [58%] 292 [57%] 76 [61%]
 Current smoker 54 [9%] 44 [9%] 10 [8%]
 Former smoker 213 [33%] 174 [34%] 39 [31%]
Disease extent at diagnosis, n [%]
 E1: proctitis 144 [20%] 118 [20%] 26 [21%]
 E2: left-sided 291 [41%] 233 [40%] 58 [46%]
 E3: extensive colitis 273 [39%] 231 [40%] 42 [33%]
Cumulative frequency and duration of medical treatment
n [%] Months, median 
[IQR]
n [%] Months, median 
[IQR]
n [%] Months, median 
[IQR]
5-aminosalicylate 535 [91%] 49 [19–62] 126 [100%] 45 [24–63] 661 [92%] 49 [20–62]
Prednisolone 305 [52%] 4 [1–3] 56 [44%] 3 [2–6] 361 [50%] 4 [2–6]
Immunomodulators 176 [30%] 29 [8–49] 34 [27%] 25 [9–48] 210 [29%] 28 [8–49]
Biological therapy 70 [12%] 14 [5–28] 10 [8%] 19 [10–32] 80 [11%] 14 [6–29]
IQR, interquartile range.
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During follow-up, 99 [14%] patients received systemic GCS for 
a cumulative period longer than 6  months, and 47 [7%] patients 
received this treatment for more than 6 consecutive months, with 
no geographical difference observed in either case. Of those receiv-
ing GCS for more than 6 consecutive months, most patients had 




























































Follow-up End of follow-up
Figure 2. Disease extent and changes in extent in ulcerative colitis patients during 5 years of follow-up in a European population-based inception cohort. The 
figure shows disease extent at diagnosis, the greatest extent during follow-up, and the extent at the end of follow-up.
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Furthermore, 18 [38%] of those patients went on to receive immu-
nomodulators as their highest treatment step (Western Europe: 17 
[44%); Eastern Europe: 1 (13%]), 13 [28%] were treated with bio-
logics (Western Europe: 9 [23%]; Eastern Europe: 4 [50%]), and 
seven [15%] had a subsequent colectomy (Western Europe: 7 [18%]; 
Eastern Europe: 0 [0%]).
A total of 80 [11%] UC patients were treated with biologics dur-
ing follow-up (Western Europe: 70 [12%]; Eastern Europe: 10 [8%]; 
p > 0.05). Most patients received infliximab as the initial type of bio-
logical treatment [infliximab: n = 72, 90%; adalimumab: n = 7, 9%; 
golimumab: n  =  1, 1%]. Of the Western European patients, three 
[4%] patients had E1, 28 [40%] had E2. and 39 [56%] had E3, 
whereas in Eastern Europe, two [20%] patients had E1, three [30%] 
had E2, and five [50%] had E3. The data for treatment given before 
biological therapy are shown in Supplementary Table 1, available as 
Supplementary data at ECCO-JCC online.
3.3. Hospitalisation
A total of 163 [23%] patients were hospitalised at least once because 
of UC. The majority of those [n = 151, 93%] hospitalisations were 
for UC-related reasons [medical hospitalisation], and the others 
were due to surgery [n = 12, 7%]. More patients in Western Europe 
Table 3. Factors associated with hospitalisation and surgery in 273 ulcerative colitis patients with extensive colitis in the Epi-IBD-cohort
Hospitalisation, all Hospitalisation, only medical Surgery
Age at diagnosis [per year] 0.98 [0.97–0.99]* 0.98 [0.96–0.99]* 0.99 [0.96–1.02]
Sex
 Female 1.0 [0.7–1.6] 1.2 [0.8–1.9] 1.0 [0.4–2.5]
 Male reference reference reference
Diagnostic delay [per day] 1.0 [1.0–1.0] 1.0 [1.0–1.0] 1.0 [1.0–1.0]
Geographical region
 Eastern Europe 0.8 [0.4–1.5] 0.8 [0.4–1.5] 0.7 [0.2–2.6]
 Western Europe reference reference reference
Smoking status at diagnosis
 Currently 0.9 [0.4–2.2] 1.1 [0.5–2.5] 0.5 [0.1–4.2]
 Former 1.2 [0.7–1.9] 1.3 [0.8–2.3] 1.2 [0.5–3.0]
 Never reference reference reference
Extra-intestinal manifestations at diagnosis 1.4 [0.8–2.6] 1.4 [0.7–2.5] 1.8 [0.6–5.0]
Use of immunomodulators 0.5 [0.2–0.9]* 0.5 [0.3–0.9]* 0.7 [0.3–2.0]
Use of biologicals 1.0 [0.4–2.6] 0.8 [0.3–2.3] 1.8 [0.6–5.5]
Need for early corticosteroids 1.8 [1.2–2.8]* 1.8 [1.2–2.9]* 2.0 [0.8–4.8]
Regression to proctitis or left-sided colitis
 Yes 0.1 [0.01–0.4]* 0.1 [0.01–0.5]* 0.4 [0.1–1.4]
 No reference reference reference
*P < 0.05.
Table 2. Factors associated with progression in disease extent, hospitalisation, and surgery in ulcerative colitis patients in the Epi-IBD-cohort.
Progression in extent 
[n = 435]







Age at diagnosis [per year] 0.98 [0.96–0.99]* 1.00 [0.99–1.02] 0.98 [0.97–0.99]* 0.98 [0.97–0.99]* 0.99 [0.97–1.01]
Sex
 Female 0.9 [0.6–1.5] 0.7 [0.4–1.3] 1.3 [0.9–1.7] 1.3 [0.9–1.8] 1.2 [0.7–2.4]
 Male reference reference reference reference reference
Diagnostic delay [per day] 1.0 [1.0–1.0] 1.0 [0.9–1.0] 1.0 [1.0–1.0] 1.0 [1.0–1.0] 1.0 [1.0–1.0]
Geographical region
 Eastern Europe 0.6 [0.3–1.2] 0.9 [0.4–1.8] 0.6 [0.4–0.9]* 0.6 [0.4–0.97]* 0.3 [0.1–1.1]
 Western Europe reference reference reference reference reference
Smoking status at diagnosis
 Currently 1.1 [0.5–2.8] 0.7 [0.3–2.1] 0.7 [0.4–1.4] 0.7 [0.4–1.4] 0.3 [0.1–2.4]
 Former 1.2 [0.7–2.1] 1.1 [0.6–1.9] 1.1 [0.7–1.5] 1.1 [0.8–1.7] 1.3 [0.7–2.7]
 Never reference reference reference reference reference
Disease extent - -
 E3: extensive colitis 1.4 [1.4–4.1]* 2.2 [1.3–3.8]* 3.5 [1.01–12.3]*
 E2: left-sided colitis 1.5 [0.9–2.6] 1.4 [0.8–2.3] 2.3 [0.7–8.1]
 E1: proctitis reference reference reference
Extra-intestinal manifestations at 
diagnosis
1.3 [0.6–2.8] 0.6 [0.3–1.4] 1.4 [0.9–2.2] 1.4 [0.9–1.0] 1.3 [0.5–3.1]
Use of immunomodulators 0.6 [0.3–1.1] 0.7 [0.4–1.3] 0.5 [0.3–0.8]* 0.5 [0.3–0.8]* 1.3 [0.7–2.7]
Use of biologicals 0.7 [0.2–2.2] 1.5 [0.8–2.8] 0.8 [0.3–1.7] 0.6 [0.1–1.4] 1.4 [0.6–3.2]
Need for early corticosteroids 1.1 [0.6–2.2] 1.4 [0.8–2.3] 1.7 [1.2–2.4]* 1.8 [1.3–2.6]* 0.9 [0.5–1.9]
*p < 0.05’
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[n = 142, 24%] were hospitalised than in Eastern Europe [n = 21, 
17%; p  <  0.05] [Figure  5a]. The median time to first hospitalisa-
tion was 10 months [IQR: 3–23] and the median number of hospi-
talisations per patient was one [IQR: 1–2], a figure similar in both 
Western and Eastern Europe. Data regarding treatment preceding 
hospitalisation are shown in Supplementary Table 1.
When looking only at medical hospitalisations, 153 [22%] 
patients were hospitalised at least once after a median of 10 months 
[IQR: 3–22] until first hospitalisation, with no geographical differ-
ences. In Western Europe, 133 [23%] patients were hospitalised 
as compared with 29 [16%] patients in Eastern Europe [p = 0.06] 
[Figure  5a]. The median number of medical hospitalisations per 
patient was one [IQR: 1–1], which was similar in Western and Eastern 
Europe. In Western Europe, one [1%] patient underwent surgery as 
their highest treatment step before hospitalisation, six [5%] patients 
received biologics, 20 [15%] patients received immunomodulators, 
and 70 [53%] received GCS. In Eastern Europe, five [25%] patients 
received immunomodulators, seven [35%] received GCS, and no 
patients received biologics or underwent surgery. Predictors associ-
ated with medical hospitalisation are shown in Table 2.
3.4. Surgery
A total of 43 [6%] UC patients underwent a colectomy during 
follow-up, of which the majority of operations took place within 
the first 2  years after diagnosis [n  =  29, 67%] and significantly 
more came from Western [n = 40, 7%] than from Eastern [n = 3, 
2%; p < 0.05] Europe [Figure 5b]. At 11 months [IQR: 4–31], the 
median time to colectomy did not differ between regions. Among 
Western European patients, three [8%] had E1, 16 [40%] had E2, 
and 21 [53%] had E3, whereas all Eastern European patients had 
E3. Predictors associated with surgery are shown in Table  2. The 
difference in colectomy rates between regions was significant in 
the univariate analysis, but this was not the case in the multivari-
ate Cox regression model [East vs West HR: 0.3 95% CI: 0.1–1.1]. 
Data regarding the highest treatment step reached before surgery are 
shown in Supplementary Table 1. Of those 43 patients, 24 [56%] 
subsequently received a pouch during the follow-up period.
Mayo endoscopic subscores were available for 635 [89%] 
patients during the first year following their diagnosis. Of those 
patients, 255 [40%] achieved mucosal healing. Other than those 
undergoing colectomy during the first year [n = 23], patients who 
did not experience mucosal healing during the first year had a 
non-significantly increased risk of colectomy in subsequent years 
[HR: 2.3 95% CI: 0.8–6.2] [Supplementary Figure  2, available 
as Supplementary data at ECCO-JCC online]. Other covariates, 
including biological therapy, were not found to influence the risk of 
colectomy in a statistically significant way, either.
3.5. Cancer and death
A total of 14 [2%] patients were diagnosed with 15 cancers a median 
of 34 months after their diagnosis [IQR: 11–48]. Colorectal cancer 
occurred in two patients; all others were extra-intestinal cancers 
[one stomach, three breast, one urinary tract, three lung, three skin, 
one brain, one cancer in the female genital organs].
During follow-up, eight [1%] patients died a median of 
35  months [IQR: 22–44] after their diagnosis. One patient died 
because of respiratory complications following colectomy, whereas 
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Figure 3. Cumulative 5-year exposures for medical treatment of patients with ulcerative colitis in a European inception cohort for the entire cohort, as well as in 
A] Eastern Europe and B] Western Europe. 5-ASA, 5-aminosalicylates
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4. Discussion
We have presented the real-life disease course and treatment strate-
gies of UC in the era of biological therapy and widespread use of 
immunomodulators. Although patients were treated earlier and 
more aggressively with immunomodulators and biological therapy 
as compared with population-based cohorts from the previous 
two decades, disease outcomes, including the frequency of colec-
tomy and rates of disease progression, did not differ substantially. 
Treatment strategies did differ between Eastern and Western Europe 
in that patients were treated earlier, but not more frequently, with 
immunomodulators and biological therapy and more patients went 
untreated in Western Europe; nonetheless, disease outcomes were 
similar. Finally, we found that immunomodulators reduced the risk 
of hospitalisation and the risk of progression, but the latter did not 
appear to be statistically significant.
Whether colectomy rates have decreased as a result of recent 
changes in UC management remains uncertain. In the present cohort, 
6% of patients had a colectomy after 5 years, a figure similar both 
in concurrent cohorts5,18–20 and in older cohorts from the 1990s.21,22 
Time-trend studies have associated increasing and earlier use of 
immunomodulators and biological therapy with reduced rates of 
colectomy.4,23 However, several recent population-based cohort stud-
ies have found that colectomy rates were already decreasing before 
the advent of biological therapy and have remained stable during the 
past two decades.5,18,24 A meta-analysis of population-based cohort 
studies also found that colectomy rates 5 years after diagnosis had 
not decreased over time.25 Similar to the European Collaborative 
Study Group of Inflammatory Bowel Disease [EC-IBD] cohort, the 
majority of patients underwent colectomy during the first 2  years 
of follow-up,22 suggesting severe disease activity in those patients. 
However, after 5 years of follow-up, indications were of colectomy 
change from fulminant or refractory colitis to, among others, corti-
costeroid-dependent or chronically active disease. It remains to be 
proven that current treatment strategies for maintenance therapy 
can influence the disease course in the long term.
Data about immunomodulators such as azathioprine and their 
use as disease modifiers in UC are limited, and current clinical prac-
tice around azathioprine treatment of UC is based on minimal and 
controversial evidence.26 Whereas biological therapy was not associ-
ated with the risk of either surgery or hospitalisation, immunomodu-
lators—as was the case in our findings regarding CD7—significantly 
reduced the risk of hospitalisation. Hence, further studies are needed 
in order to determine their efficacy for treating UC. It is worth men-
tioning that treatment with immunomodulators was included as a 
time-dependent variable in the analysis with a 3-month lag time, and 
that the association was also found to be significant in the subanaly-
sis of patients with extensive colitis.
In our study, significantly fewer patients in Eastern Europe 
underwent a colectomy than in Western Europe, yet the figures 











































































Figure 4. The time-varying distribution of ulcerative colitis patients receiving different levels of treatment on any given day during follow-up for the entire 
cohort, as well as in A] Eastern Europe and B] Western Europe. Patients receiving combination therapy will appear in each of the respective curves, thus the 
curves will not add up to 100%. 5-ASA, 5-aminosalicylates
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patient characteristics did not differ between the regions.27 However, 
in our multivariate analysis taking also patient and disease charac-
teristics into consideration, geographical region was not significantly 
associated with the risk of surgery. In the EC-IBD cohort, regional 
differences in colectomy rates were noted as well, and these can-
not be explained by differences in disease course alone.22 Regional 
factors such as attitudes towards surgery, availability of treatments, 
and prevalence of bacterial superinfections might have contributed 
to these differences.
The extent to which the colon is involved in UC can change over 
time, having a significant impact on treatment choices, disease sever-
ity, and prognosis.28–30 We found that one in five patients with proc-
titis or left-sided colitis progressed to extensive colitis, in accordance 
with a recent systematic review of 41 studies31 as well as other recent 
population-based studies.5,32 Our data therefore indicate that the rate 
of progression has not changed during the past decade. The data also 
indicate that the use of biological therapy and immunomodulators 
does not appear to have statistically reduced the risk of disease pro-
gression. Furthermore, of patients in our cohort diagnosed with, or 
who progressed to, extensive colitis, approximately 30% regressed 
during follow-up. A recent study from the Swiss IBD cohort found 
that 16% of patients experienced a regression of extent; however, 
this difference could be due to differences in study design as this 
was not a population-based study. Only two Scandinavian popula-
tion-based cohorts, from 1962 to 198733 and 1991 to 1993,34 have 
assessed the rates of regression of extent and, to our knowledge, ours 
is the first population-based cohort study to do so since the introduc-
tion of biological therapy. We have also demonstrated that patients 
diagnosed with extensive colitis, and who experienced a regression 
in extent due to medical therapy, had a significantly lower risk of 
hospitalisation but the reduced risk for undergoing a colectomy did 
not reach statistical significance.
Finally, we have examined treatment choices, as well as changes 
in treatments over time, in a cohort representative of the whole UC 
population. The use of biological therapy in UC increased during fol-
low-up but was used in less than 10% of patients on any given day. 
These figures are similar to those found in other recent cohorts,35–37 
although patients were started on immunomodulators earlier in the 
present study. In contrast to CD,7 treatment with biologicals did not 
differ between regions, although the treatment duration was longer 
in Eastern European patients as were the treatments used before ini-
tiation of biological therapy. However, and as discussed previously, 
these differences did not result in different surgery, hospitalisation, 
or disease progression rates. Choices regarding investigations and 
medical and surgical treatments, as well as their availability, are 
closely linked to extra-medical considerations and therefore the dif-
ferences observed between Western and Eastern Europe might have 
been caused by considerable variations between national health care 
systems. A proportion of patients [7%] were treated with corticos-
teroids for more than 6 months and a similar proportion did not 
receive any medical treatment at all during follow-up. Whereas this 
contradicts recent guidelines,38 these decisions might be influenced 
by patient or physician preference or patient non-compliance.
Strengths of the present study include the prospective inclusion 
and follow-up of incident IBD patients diagnosed within well-defined 
geographical areas. Diagnostic criteria, case ascertainment methods, 
and the recorded data were all standardised. Several measures pre-
viously described8 ensured that all centres contributed good quality, 
valid data to this study. The patients were unselected and represent 
the whole spectrum of disease severity; therefore, the choices of 
treatment in this cohort are the result of community effectiveness 
rather than the requirements of a randomised controlled trial, and 
they all occurred in a real-life clinical setting.
Limitations of this study include its observational design and the 
heterogeneity of the participating centres in terms of the health care 
systems of which they are a part. In addition, the distribution of 
participating centres is skewed, as the Eastern European centres are 
in mostly low-incident areas1 and hence a majority of patients in this 
study originate in Western Europe. However, and as in previous find-
ings,7,39 the patient populations from Western and Eastern Europe 
were similar in terms of socioeconomic characteristics, disease classi-
fication, diagnostic procedures used, and length of diagnostic delay.8 
Therefore, we have no reason to believe that the region of origin 
influenced the disease course. However, the absence of geographical 
differences in treatment outcomes as well as differences in outcomes 
compared with previous cohorts might not reflect true non-differ-
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Figure 5. Cumulative probability for hospitalisation [A] and surgery [B] during the first 5 years of disease in a European population-based cohort of ulcerative 
colitis patients.
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In conclusion, we have found that in this prospective, popula-
tion-based cohort of unselected UC patients, patients were treated 
earlier and more aggressively with immunomodulators and bio-
logical therapy than were cohorts from the beginning of the bio-
logical era. However, 5-year surgery, hospitalisation, and disease 
progression rates are similar to cohorts from 20 years ago. The use 
of immunomodulators appeared to improve the disease course of 
UC in terms of the risk of hospitalisation, but we could not demon-
strate a comparable benefit in the use of biological therapy.
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